← Back to Search

Nirmatrelvir plus ritonavir for Post-COVID Syndrome (STOP-PASC Trial)

Phase 2

Waitlist Available

Led By Upinder Singh, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up weeks 5, 10, and 15

Awards & highlights

STOP-PASC Trial Summary

This trial will test a drug (Paxlovid) to see if it reduces symptoms of Long Covid better than a placebo. It will involve 5 visits over 15 weeks.

Eligible Conditions

Post-COVID Syndrome
COVID-19

STOP-PASC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ weeks 5, 10, and 15

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~weeks 5, 10, and 15

This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 5, 10, and 15 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Change in 1-minute sit-to-stand test

Change in PROMIS Cognitive Function Abilities Score

Change in PROMIS Dyspnea-Severity Score

+10 more

STOP-PASC Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Nirmatrelvir plus ritonavirExperimental Treatment2 Interventions

Participants receive nirmatrelvir plus ritonavir (Paxlovid) for 15 days, and attend follow-up visits through week 15.

Group II: Placebo plus ritonavirPlacebo Group2 Interventions

Participants receive placebo to match nirmatrelvir plus ritonavir for 15 days, and attend follow-up visits through week 15.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ritonavir

2005

Completed Phase 4

~2200

Nirmatrelvir

2022

Completed Phase 2

~330

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,389 Previous Clinical Trials

17,334,559 Total Patients Enrolled

PfizerIndustry Sponsor

4,568 Previous Clinical Trials

10,911,718 Total Patients Enrolled

1 Trials studying Post-COVID Syndrome

400 Patients Enrolled for Post-COVID Syndrome

Upinder Singh, MDPrincipal InvestigatorStanford University

1 Previous Clinical Trials

122 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still an opportunity to join this research endeavor?

"According to the records on clinicaltrials.gov, this medical trial is currently open for patient recruitment and has been since November 8th 2022. The information was last amended on November 16th of the same year."

Answered by AI

What potential risks are associated with Nirmatrelvir plus ritonavir therapy?

"A score of 2 was given to Nirmatrelvir plus ritonavir in terms of safety due to limited data that suggests it is safe, but no efficacy studies have been conducted yet."

Answered by AI

What is the upper limit of participants in this research endeavor?

"Affirmative. According to clinicaltrials.gov, this research endeavour is currently recruiting participants for the trial which was initially posted on November 8th 2022 and revised on the 16th of that month. The study requires 200 patients from a single site to join in order to be completed successfully."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Paxlovid for Treatment of Long Covid

2022. "Paxlovid for Treatment of Long Covid". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05576662.